Baidu, Inc. (BIDU) Reaches $257.26 After 8.00% Down Move; Last Week Globus Medical, Inc. (GMED) Analysts

May 18, 2018 - By Dolores Ford

Baidu, Inc. (NASDAQ:BIDU) Logo

Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Globus Medical Inc had 51 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 3 by Canaccord Genuity. The stock has “Overweight” rating by Morgan Stanley on Tuesday, January 2. The stock of Globus Medical, Inc. (NYSE:GMED) has “Buy” rating given on Monday, December 4 by Wells Fargo. The firm has “Buy” rating by UBS given on Tuesday, September 22. Bank of America upgraded the stock to “Neutral” rating in Friday, November 10 report. The firm has “Hold” rating by Oppenheimer given on Thursday, March 23. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Buy” rating by Canaccord Genuity on Tuesday, September 19. On Tuesday, July 18 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Buy” rating by Piper Jaffray on Tuesday, January 2. As per Monday, October 23, the company rating was maintained by Canaccord Genuity. See Globus Medical, Inc. (NYSE:GMED) latest ratings:




03/05/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $53 New Target: $58 Maintain
03/05/2018 Broker: Needham Rating: Buy New Target: $58.0000 Maintain
16/04/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $37 Downgrade
04/04/2018 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $60.0000 Maintain
22/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $54.0 Maintain
22/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $53.0 Maintain
22/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $48 New Target: $53 Maintain
09/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $50.0 Maintain
04/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $47.0 Maintain

The stock of Baidu, Inc. (NASDAQ:BIDU) is a huge mover today! The stock decreased 8.02% or $22.42 during the last trading session, reaching $257.26. About 9.66M shares traded or 246.29% up from the average. Baidu, Inc. (NASDAQ:BIDU) has risen 36.72% since May 18, 2017 and is uptrending. It has outperformed by 25.17% the S&P500.The move comes after 8 months negative chart setup for the $89.71 billion company. It was reported on May, 18 by Barchart.com. We have $236.68 PT which if reached, will make NASDAQ:BIDU worth $7.18B less.

The stock increased 0.35% or $0.18 during the last trading session, reaching $51.25. About 223,503 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 65.36% since May 18, 2017 and is uptrending. It has outperformed by 53.81% the S&P500.

Investors sentiment decreased to 0.99 in 2017 Q4. Its down 0.39, from 1.38 in 2017Q3. It dived, as 26 investors sold Globus Medical, Inc. shares while 83 reduced holdings. 40 funds opened positions while 68 raised stakes. 59.89 million shares or 7.54% less from 64.77 million shares in 2017Q3 were reported. The New York-based Gotham Asset Mngmt Limited Company has invested 0.18% in Globus Medical, Inc. (NYSE:GMED). The Illinois-based Guggenheim Capital Ltd Co has invested 0.02% in Globus Medical, Inc. (NYSE:GMED). Thomson Horstmann & Bryant reported 11,700 shares. 990 were reported by Vantage Investment Ltd Co. Keybank Association Oh accumulated 6,941 shares. Tower Research Ltd (Trc) accumulated 403 shares or 0% of the stock. 5,432 were reported by Shelton Capital Mngmt. Wellington Management Grp Incorporated Llp owns 6.70 million shares for 0.06% of their portfolio. Stratos Wealth Prtn Ltd has invested 0% of its portfolio in Globus Medical, Inc. (NYSE:GMED). Natixis reported 35,276 shares. Reilly Advisors invested in 472 shares or 0% of the stock. Eagle Asset has 0.03% invested in Globus Medical, Inc. (NYSE:GMED) for 114,636 shares. Comerica Bancshares reported 0.02% in Globus Medical, Inc. (NYSE:GMED). Ameritas Invest Prtn invested in 73,150 shares. New Mexico Educational Retirement Board invested 0.03% of its portfolio in Globus Medical, Inc. (NYSE:GMED).

More important recent Globus Medical, Inc. (NYSE:GMED) news were published by: Globenewswire.com which released: “Globus Medical Announces Positive Clinical Results for Lateral Expandable Technology” on May 15, 2018, also Seekingalpha.com published article titled: “Globus Medical: Innovating Beyond The Spine Market”, Globenewswire.com published: “Globus Medical Reports First Quarter 2018 Results” on May 02, 2018. More interesting news about Globus Medical, Inc. (NYSE:GMED) was released by: Seekingalpha.com and their article: “Globus Medical (GMED) Q1 2018 Results – Earnings Call Transcript” with publication date: May 03, 2018.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $4.98 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 46.59 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

Baidu, Inc. provides Internet search services in China and internationally. The company has market cap of $89.71 billion. It operates through three divisions: Search Services, Transaction Services, and IQiyi. It has a 30.94 P/E ratio. It offers Chinese language search platform on its Baidu.com Website that enables users to find relevant information online, including Web pages, news, images, documents, and multimedia files through links provided on its Website; and transaction platform, including Nuomi.com to connect online and offline services provided by third-parties.

Analysts await Baidu, Inc. (NASDAQ:BIDU) to report earnings on July, 26. They expect $2.15 EPS, up 6.44% or $0.13 from last year’s $2.02 per share. BIDU’s profit will be $749.77M for 29.91 P/E if the $2.15 EPS becomes a reality. After $2.25 actual EPS reported by Baidu, Inc. for the previous quarter, Wall Street now forecasts -4.44% negative EPS growth.

Among 27 analysts covering Baidu (NASDAQ:BIDU), 13 have Buy rating, 2 Sell and 12 Hold. Therefore 48% are positive. Baidu had 70 analyst reports since July 28, 2015 according to SRatingsIntel. Brean Capital downgraded Baidu, Inc. (NASDAQ:BIDU) on Tuesday, July 28 to “Hold” rating. Jefferies maintained it with “Buy” rating and $203 target in Thursday, May 12 report. The stock of Baidu, Inc. (NASDAQ:BIDU) earned “Overweight” rating by Morgan Stanley on Thursday, February 15. The firm has “Underweight” rating given on Monday, December 19 by Cantor Fitzgerald. The stock of Baidu, Inc. (NASDAQ:BIDU) earned “Neutral” rating by Citigroup on Monday, June 13. Credit Agricole downgraded the shares of BIDU in report on Tuesday, July 28 to “Underperform” rating. The stock has “Hold” rating by Summit Research on Wednesday, September 30. The company was maintained on Tuesday, October 27 by TH Capital. Bernstein upgraded the shares of BIDU in report on Friday, May 11 to “Market Perform” rating. The stock has “Buy” rating by Jefferies on Friday, October 27.

More notable recent Baidu, Inc. (NASDAQ:BIDU) news were published by: Seekingalpha.com which released: “Baidu COO will step down; shares -6%” on May 18, 2018, also Seekingalpha.com with their article: “Baidu: A Lot To Like” published on May 07, 2018, Schaeffersresearch.com published: “S&P, Nasdaq Lower on Trade Worries, Tech Slide” on May 18, 2018. More interesting news about Baidu, Inc. (NASDAQ:BIDU) were released by: Schaeffersresearch.com and their article: “2 Stocks Sinking on Surprise C-Suite Exits” published on May 18, 2018 as well as Benzinga.com‘s news article titled: “Baidu Set For 20% Growth After iQIYI Spinoff, Bernstein Says In Upgrade” with publication date: May 11, 2018.

Globus Medical, Inc. (NYSE:GMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: